Funds move lead candidate PROT-001 into a pivotal study.
- Amount
- $130M
- Stage
- Series B
- Announced
- 1 December 2025
- Lead
- Novartis Venture Fund
- Other investors
- Forbion, Omega Funds, Droia Ventures, YK Bioventures, Digitalis Ventures
- Use of funds
- Funds move lead candidate PROT-001 into a pivotal study.
- Checked
- Announced by the company